Article

Generation of Monoclonal Antibodies and Development of Sandwich ELISA for 9-valent HPV Vaccines

2025-07-24

Abstract excerpt

Cervical cancer is one of the most common cancers affecting women globally, and nearly all cases of cervical cancer were caused by human papillomavirus (HPV) infection. HPV vaccination has proven to be effective strategy in preventing HPV infection. In this study, for the nine-valent HPV vaccines (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58), we have generated subtype-specific mouse monoclonal antibodies for all nin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 62478729-09f5-5e86-b66b-e6a1db0e602c
DOI: 10.1101/2025.07.23.25332104

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Generation of Monoclonal Antibodies and Development of Sandwich ELISA for 9-valent HPV VaccinesDOI 10.1101/2025.07.23.25332104Read

Development of Neutralizing Monoclonal Antibodies for Oncogenic Human Papillomavirus Types 31, 33, 45, 52, and 58Semantic proximity Read

Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in MiceSemantic proximity Read

Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle StructuresSemantic proximity Read

L2 epitope presenting virus-like particles as broad- spectrum vaccine candidates targeting genus beta human papillomavirusesSemantic proximity Read

Potential of Recombinant Chimeric HPV16 L1/L2 VLPs Produced by Distinct Cell Lineages Such as Prophylactic Nanovaccine and Therapeutic Drug NanocarriersSemantic proximity Read

Identification and validation of immunogenic potential of India specific HPV-16 variant constructs: In-silico &in-vivo insight to vaccine development.Semantic proximity Read

Design of a multi-epitope vaccine against cervical cancer using immunoinformatics approachesSemantic proximity Read

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?Semantic proximity Read

A systematic and reverse vaccinology approach to design novel subunit vaccines against Dengue virus type-1 (DENV-1) and human Papillomavirus-16 (HPV-16)Semantic proximity Read

Rational design of a cross-type HPV vaccine through immunodominance shift guided by a cross-neutralizing antibodySemantic proximity Read

HPV16 neutralizing monoclonal antibodies show evidence for common developmental pathways and public epitopesSemantic proximity Read

Progress in L2-Based Prophylactic Vaccine Development for Protection against Diverse Human Papillomavirus Genotypes and Associated DiseasesSemantic proximity Read